

RNAI TECHNOLOGIES AND GLOBAL MARKETS



BIO127A
October 2013

Faqing Yuan
Project Analyst

ISBN: 1-56965-602-9

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
METHODOLOGY AND INFORMATION SOURCES	3
INTENDED AUDIENCE	3
ANALYST CREDENTIALS	3
RELATED REPORTS	3
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, 2011-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 INTRODUCTION TO RNAI TECHNOLOGIES	9
OVERVIEW	9
RNAI DISCOVERY	10
RNAI GENE-SILENCING MECHANISM	10
<i>FIGURE 1 SIMPLIFIED SCHEMATIC REPRESENTATION OF THE RNAI MECHANISM</i>	10
MICRORNA	11
<i>TABLE 1 MICRORNA DATABASES</i>	12
<i>TABLE 2 COMPUTATIONAL TOOLS FOR MIRNA TARGET PREDICTION</i>	13
RNAI APPLICATIONS	13
RNAI RESEARCH TOOLS AND REAGENTS	13
RNAI DRUG DEVELOPMENT	13
RNAi Drug Delivery	14
Stability	14
Size Limitation	14
Cellular Uptake	15
Immune Response Activation	15
Targeting	15
RNAi Drug Design	15
RNAI DIAGNOSTICS: MICRORNA DIAGNOSTICS	16
RNAI IN AGRICULTURE	16
RNAI MARKET OVERVIEW	16
<i>TABLE 3 GLOBAL PHARMACEUTICAL MARKET, MARKET SHARES BY REGION AND TOP COMPANIES (%/\$ MILLIONS/\$ BILLIONS)</i>	17
RNAI AS A POSSIBLE TECHNOLOGICAL PREMATUREITY	18
MERCK AND RNAI	18
Acquisition of Sirna Therapeutics	18
Shut Down RNAi Research Center	19
Merck's Continued Interests in RNAi	19
ROCHE AND RNAI	20

TOPIC	PAGE NO.
Alliance with Alnylam	20
Alliance Termination	20
Transfers RNAi Assets to Arrowhead Research	20
PFIZER AND RNAI	20
NOVARTIS AND RNAI	21
ABBOTT AND RNAI	21
ALNYLAM AND RNAI	21
Alnylam and Tekmira	21
Kyowa Hakko, Ascleptis and Sanofi Alliances	22
Future of Alnylam	22
TEKMIRA'S PARTNERS	22
DICERNA PHARMACEUTICALS FINANCING	23
REGULUS INITIAL PUBLIC OFFERING	23
MARINA-DEBIOPHARM PARTNERSHIP	24
INTELLECTUAL PROPERTY IN THE RNAI MARKETPLACE	24
<i>TABLE 4 COMPARISON OF U.S. AND EUROPEAN PATENT SYSTEMS</i>	24
U.S. SUPREME COURT: HUMAN GENES CANNOT BE PATENTED	25
PATENT ANALYSIS	26
<i>TABLE 5 PATENT AND PATENT APPLICATION SEARCHES IN RNAI MARKETPLACE USING VARIOUS KEY WORDS, AS OF AUGUST 2013</i>	27
<i>TABLE 6 PATENTS AND PATENT APPLICATIONS FOR RNAI DRUG COMPANIES, AS OF AUGUST 2013</i>	28
RNAI MARKETPLACE FUTURE	28
CHAPTER 4 RNAI RESEARCH TOOL AND REAGENT MARKET	31
OVERVIEW	31
THERMO FISHER: RNAI RESEARCH TOOLS AND REAGENTS	31
<i>FIGURE 2 THERMO FISHER RNAI PRODUCT SELECTION</i>	32
SIRNA PRODUCTS	32
ON-TARGETplus siRNA	32
siGENOME siRNA	32
Accell siRNA	33
Lincode siRNA	33
Custom siRNA Synthesis	33
SHRNA PRODUCTS	33
SMARTchoice Lentiviral shRNA	33
TRC Lentiviral shRNA	33
GIPZ Lentiviral shRNA	33
TRIPZ Inducible Lentiviral shRNA	34
MICRORNA PRODUCTS	34
miRIDIAN microRNA Mimics	34
miRIDIAN microRNA Hairpin Inhibitors	34
SMARTchoice shMIMIC Lentiviral microRNAs	34
CUSTOM RNA SYNTHESIS	34
siRNA Customization	34
Single-Stranded RNA Synthesis	35
RNAI CONTROLS	35
RNAI SCREENING LIBRARIES	35

TOPIC	PAGE NO.
Human siRNA Libraries	35
RTF siRNA Libraries	35
Duet siRNA Libraries	35
GIPZ Lentiviral shRNA Libraries	35
TRC Lentiviral shRNA Libraries	36
Custom siRNA and microRNA Libraries	36
Mouse siRNA Libraries	36
Human Lincode siRNA Libraries	36
miRIDIAN microRNA Libraries	36
TRIPZ Inducible Lentiviral shRNA Libraries	36
Decode Pooled Lentiviral shRNA Libraries	36
TRANSFECTION REAGENTS	36
VIRAL PACKAGING SYSTEMS	37
Trans-Lentiviral shRNA Packaging Kits	37
Trans-Lentiviral ORF Packaging Kits	37
RNAI ANCILLARY REAGENTS	37
LIFE TECHNOLOGIES: RNAI RESEARCH TOOLS AND REAGENTS	37
SIRNA PRODUCTS	37
Silencer Pre-Designed siRNAs	38
Stealth RNAi siRNA	38
Silencer Select siRNAs from Ambion	38
MICRORNA PRODUCTS	38
RNAI TRANSFECTION PRODUCTS	38
<i>TABLE 7 RECOMMENDED RNAI DELIVERY METHODS</i>	39
IN VIVO SIRNA ANALYSIS	39
VECTOR-BASED RNAI	39
NON-CODING RNA	39
OTHER PRODUCTS	40
SIGMA-ALDRICH: RNAI RESEARCH TOOLS AND REAGENTS	40
OTHER SIGNIFICANT PLAYERS IN THE MARKET	40
OPPORTUNITIES FOR MIDDLE- AND SMALL-SIZE COMPANIES	40
INDUSTRY ANALYSIS	41
<i>TABLE 8 GLOBAL REAGENT AND RESEARCH TOOL FOR DNA AND RNA RESEARCH MARKET, THROUGH 2016 (\$ BILLIONS)</i>	41
SUMMARY OF RNAI RESEARCH TOOLS AND REAGENTS MARKET	42
<i>TABLE 9 GLOBAL RNAI RESEARCH TOOL AND REAGENT MARKET, THROUGH 2018 (\$ MILLIONS)</i>	43
<i>FIGURE 3 GLOBAL RNAI RESEARCH TOOL AND REAGENT MARKET, 2011-2018 (\$ MILLIONS)</i>	43
CHAPTER 5 RNAI DRUG DELIVERY	45
OVERVIEW	45
BARRIERS FOR RNAI DRUG DELIVERY	46
RNA STABILITY	46
MOLECULAR DIFFUSION AND IMMUNE DEFENSE	46
CELL PENETRATION	46
Mechanism of Lipid-Based RNAi Delivery	47
TISSUE TARGETING: PREFERENTIAL DISTRIBUTION TO TARGETS	47

TOPIC	PAGE NO.
<i>TABLE 10 MAJOR OBSTACLES FOR RNAI DRUG DELIVERY</i>	48
GOALS FOR RNAI DRUG DELIVERY	48
SIRNA DELIVERY ASSAY SYSTEMS	48
RNAI DRUG DELIVERY STRATEGIES	49
METHODS FOR RNAI DRUG DELIVERY	49
<i>TABLE 11 RNAI DRUG DELIVERY APPROACHES</i>	50
PHYSICAL RNAI DELIVERY	50
HYDRODYNAMIC INTRAVENOUS INJECTION	50
ELECTROPORATION	50
VECTOR-BASED RNAI DELIVERY	51
PLASMID VECTOR RNAI DELIVERY	51
VIRAL VECTOR RNAI DELIVERY	51
CARRIER-BASED DELIVERY	52
CELL-PENETRATION PEPTIDES AND THEIR MIMICS	52
APTAMER-MEDIATED SIRNA DELIVERY	53
Aptamer-Mediated RNAi Nanocarrier Delivery	54
LIPID-BASED RNAI DELIVERY	54
Stable Nucleic Acid Lipid Particle Technology	55
<i>FIGURE 4 SCHEMATIC COMPOSITION OF STABLE NUCLEIC ACID LIPID PARTICLE TECHNOLOGY</i>	55
POLYMER-BASED SIRNA DELIVERY	56
LIPID-POLYMER COMBINED-BASED RNAI DELIVERY	57
DENTRIMER MEDIATED SIRNA DELIVERY	57
BACTERIOPHAGE PHI29 PACKAGING RNA-BASED NANOPARTICLES	57
MESOPOROUS SILICA NANOPARTICLES	58
ANTIBODY-MEDIATED RNAI DELIVERY	58
STEM-CELL-MEDIATED RNAI DELIVERY	58
LIGHT CONTROLLABLE AND OTHER SMART DELIVERY PLATFORMS	58
RNA MODIFICATIONS	59
<i>FIGURE 5 MODIFICATIONS TO SIRNA BACKBONES AND BASES</i>	59
PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS	60
<i>FIGURE 6 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER BACKBONE STRUCTURE</i>	60
RNAI DELIVERY SYSTEM IN CANCER RESEARCH	60
BREAST CANCER	61
OVARIAN CANCER	61
CERVICAL CANCER	62
LIVER CANCER	62
LUNG CANCER	62
PROSTATE CANCER	63
OTHERS	63
RNAI DELIVERY METHODS FOR INDIVIDUAL ORGANS	64
RESPIRATORY TRACT	64
EYE	64
BRAIN	64
GASTROINTESTINAL TRACT	65
GENITOURINARY TRACT	65
LIVER	65

TOPIC	PAGE NO.
<i>NOTABLE PROPRIETARY DELIVERY PLATFORMS</i>	65
<i>TABLE 12 PROPRIETARY DELIVERY PLATFORMS</i>	66
ALZET PUMPS FROM DURECT CORPORATION	67
DNA-DIRECTED RNAI TECHNOLOGIES FROM BENITEC	67
USIRNA, DILA2, TAURNAI AND TKRNAI FROM MARINA BIOTECH	67
PRINT TECHNOLOGY FROM LIQUIDIA	68
SIRNA-LIPOPLEX FROM SILENCE THERAPEUTICS	68
<i>TABLE 13 DELIVERY SYSTEMS FROM SILENCE'S INVOLVEMENT</i>	69
SAMIRNA TECHNOLOGY FROM BIONEER	69
LNP FROM TEKIRA	69
NANOPARTICLE FROM CERULEAN	69
SMARTT POLYMER TECHNOLOGY FROM PHASERX	70
ALNYLAM'S DELIVERY SYSTEM	70
RXI PHARMA'S SELF-DELIVERY PLATFORM	70
DYNAMIC POLYCONJUGATES, RONDEL AND HOMING PEPTIDE FROM ARROWHEAD	71
SOLSTICE BIOLOGICS	72
SUMMARY	72
CHAPTER 6 RNAI DRUG DEVELOPMENT	74
OVERVIEW	74
RNA-BASED THERAPIES	74
ANTISENSE RNA THERAPY	74
MECHANISM OF ANTISENSE THERAPY	75
Antisense Therapeutics	75
<i>TABLE 14 ISIS PHARMACEUTICALS ANTISENSE DRUG CANDIDATES</i>	76
<i>TABLE 15 ISIS PHARMACEUTICALS REVENUE, PROFIT AND STOCK PRICES (\$ MILLIONS)</i>	77
RIBOZYME AS THERAPEUTICS	78
<i>TABLE 16 RIBOZYME-BASED THERAPIES IN PRECLINICAL CANCER MODELS</i>	79
APTAMER THERAPEUTICS	79
<i>TABLE 17 APTAMERS AND THEIR TARGETS</i>	80
<i>TABLE 18 APTAMER DRUGS IN VARIOUS CLINICAL STAGES</i>	81
MESSENGER RNA THERAPEUTICS	81
RNAI DRUG DISCOVERY AND THERAPEUTICS	82
CHALLENGES OF RNAI THERAPEUTICS	82
siRNA Stability and Targeting	82
Off-target Silencing	83
Activation of Immune Response and Toxicity	83
RNAI DRUG DISCOVERY STRATEGIES	83
TARGETING ENDOGENOUS MICRORNA PROCESSES	83
Down-Regulating Endogenous microRNA Functions	84
MicroRNA Replacement Therapy	84
<i>TABLE 19 RNAI THERAPEUTICS TARGETING MICRORNA</i>	84
INTRODUCING SIRNA TO CELLS	84
RNAI THERAPEUTIC DESIGN	85
RULES FOR SIRNA SEQUENCE SELECTIONS	85
<i>FIGURE 7 DESIGNING HIGHLY ACTIVE SIRNAS FOR RNAI THERAPEUTICS</i>	85

TOPIC	PAGE NO.
CHEMICAL AND STRUCTURAL MODIFICATION	86
RNAI-RELATED SOFTWARE PREDICATION TOOLS AND THEIR WEBSITES	86
<i>TABLE 20 SUMMARY OF RNAI-RELATED SOFTWARE</i>	87
RNAI-BASED THERAPEUTICS FOR VARIOUS DISEASES	87
CANCER	87
RNAi Used to Identify Novel Drug Targets in Cancer and Other Diseases	87
HUMAN IMMUNODEFICIENCY VIRUS	88
HUMAN PAPILLOMAVIRUS	88
ALZHEIMER'S DISEASE	89
<i>NOTABLE RNAI DRUG DISCOVERY COMPANIES</i>	89
ALNYLAM PHARMACEUTICALS	89
<i>TABLE 21 ALNYLAM'S OWN, PARTNERED AND LICENSED PROGRAMS</i>	90
ARROWHEAD RESEARCH CORPORATION	90
<i>TABLE 22 ARROWHEAD RESEARCH CORPORATION DRUG PIPELINE</i>	91
MARRINA BIOTECH	91
<i>TABLE 23 RNAI DRUG PIPELINE FROM MARINA BIOTECH</i>	91
TEKMIRA PHARMACEUTICALS CORPORATION	92
<i>TABLE 24 TEKIRA'S RNAI PIPELINE PROGRAMS</i>	92
BENITEC BIOPHARMA	92
<i>TABLE 25 BENITEC IN-HOUSE AND OUT-LICENSED PIPELINES</i>	93
SILENCE THERAPEUTICS	93
<i>TABLE 26 SILENCE THERAPEUTICS DRUG PIPELINE</i>	94
CERULEAN PHARMA	94
BIONEER	94
<i>TABLE 27 BIONEER'S RNAI DRUG PROGRAMS</i>	95
PHASERX	95
<i>TABLE 28 PHASERX'S PIPELINE PROGRAMS</i>	95
DICERNA PHARMACEUTICALS INC.	95
<i>TABLE 29 DICERNA'S EMERGING PIPELINE</i>	96
RXI PHARMACEUTICALS	96
<i>TABLE 30 RXI PHARMACEUTICALS PIPELINE</i>	96
QUARK PHARMACEUTICALS	96
<i>TABLE 31 QUARK DEVELOPMENT PIPELINE</i>	97
ANTISENSE VERSUS RNAI	97
<i>TABLE 32 COMPARISON OF NOTABLE RNA THERAPEUTICS COMPANIES</i>	98
RNAI DRUG DISCOVERY MARKET SUMMARY	98
<i>TABLE 33 ESTIMATED MARKET SIZE FOR THERAPEUTIC APPLICATIONS AND GEOGRAPHIC DISTRIBUTION OF RNA DRUG COMPANIES (DOLLAR VALUES AND PERCENTAGES)</i>	99
CHAPTER 7 RNAI DIAGNOSTICS	101
INTRODUCTION	101
<i>TABLE 34 PUBLICATIONS REGARDING MICRORNA AND DISEASES, AS OF AUGUST 2013</i>	101
<i>TABLE 35 GLOBAL BIOMARKER MARKET, THROUGH 2015 (\$ BILLIONS)</i>	102
MICRORNA IN HUMAN CANCER DIAGNOSTICS	102
<i>TABLE 36 MIRNAS IN VARIOUS CANCER TYPES</i>	103

TOPIC	PAGE NO.
<i>TABLE 37 MIRNA DYSREGULATION AND COLORECTAL CANCER</i>	106
MICRORNAS AS PROGNOSTIC AND PREDICTIVE BIOMARKERS	106
<i>TABLE 38 STUDIES ON THE ASSOCIATION BETWEEN MIRNA DYSREGULATION AND STAGING OR PROGNOSIS OF COLORECTAL CANCER</i>	107
<i>TABLE 39 MICRORNA UP AND DOWN REGULATION IN LUNG CANCER</i>	109
CHALLENGES ASSOCIATED WITH MICRORNA AS A BIOMARKER	109
<i>TABLE 40 IDEAL BIOMARKER CRITERIA</i>	109
<i>TABLE 41 HURDLES TO OVERCOME FOR MICRORNAS TO BE GOOD BIOMARKERS</i>	110
MICRORNA DIAGNOSTICS MARKET DRIVERS	110
SIGNIFICANT PLAYERS IN THE MICRORNA DIAGNOSTIC MARKET	110
MICRORNA BIOMARKER DIAGNOSTIC KIT FROM ROSETTA GENOMICS	110
Rosetta Cancer Origin Test	111
Rosetta Lung Cancer Test	111
Rosetta Kidney Cancer Test	111
Rosetta Mesothelioma Test	111
<i>FIGURE 8 ROSETTA GENOMICS PIPELINE</i>	112
MICRORNA PROFILING MARKET	112
<i>TABLE 42 CANCER PROFILING, THROUGH 2015 (\$ BILLIONS)</i>	112
Microna Profiling from Exiqon	113
Microna Profiling from Asuragen	113
SUMMARY AND FUTURE PERSPECTIVES	113
<i>TABLE 43 GLOBAL MICRORNA RESEARCH MARKET, THROUGH 2017 (\$ MILLIONS)</i>	114
<i>TABLE 44 GLOBAL MICRORNA DIAGNOSTIC AND MICRORNA PROFILING MARKET, THROUGH 2018 (\$ MILLIONS)</i>	114
CHAPTER 8 RNAI IN AGRICULTURE	116
INTRODUCTION	116
RNAI-BASED BIOTECHNOLOGY SAFETY CONCERNS	116
RNAI APPLICATION IN CROPS	117
<i>TABLE 45 NOVEL PLANT TRAITS ENGINEERED THROUGH RNAI</i>	117
RNAI APPLICATION IN VIRUS AND PEST CONTROL	118
RNAI APPLICATION IN AQUACULTURE	119
SUMMARY AND FUTURE PERSPECTIVE	119
CHAPTER 9 COMPANY PROFILES	122
BIG PHARMA COMPANIES	122
PFIZER	122
ROCHE	122
LARGE AGRICULTURE COMPANIES	122
MONSANTO COMPANY	122
SYNGENTA AG	123
RNAI DRUG DEVELOPMENT COMPANIES	123
ALNYLAM PHARMACEUTICALS	123
ARROWHEAD RESEARCH CORPORATION	124
QUARK PHARMACEUTICALS INC.	124
RXI PHARMACEUTICALS CORP.	125
SILENCE THERAPEUTICS	125
TEKMIRA PHARMACEUTICALS CORP.	126

TOPIC	PAGE NO.
LARGE REAGENTS COMPANIES	126
LIFE TECHNOLOGIES (TO BE MERGED WITH THERMO FISHER)	126
SIGMA-ALDRICH	126
THERMO FISHER SCIENTIFIC INC.	127
OTHER COMPANIES	127
INTEGRATED DNA TECHNOLOGIES	127
ISIS PHARMACEUTICALS	127
PROSENSA	128
REGULUS THERAPEUTICS INC.	128
ROSETTA GENOMICS	128
SAREPTA THERAPEUTICS	129
CHAPTER 10 COMPANIES MENTIONED IN THIS REPORT	131
ABBOTT LABORATORIES	131
ADVIRNA	131
AEGERA THERAPEUTICS	131
AGILENT TECHNOLOGIES	131
ALNYLAM PHARMACEUTICALS	131
ANTISENSE PHARMA GMBH	132
ANTISOMA PLC	132
APPLIED BIOLOGICAL MATERIALS INC.	132
ARADIGM CORPORATION	132
ARCA BIOPHARMA	132
ARCHEMIX	133
ARROWHEAD RESEARCH CORPORATION	133
ASCLETIS INC.	133
ASTRAZENECA PHARMACEUTICALS LP	133
ASURAGEN	133
BENITEC BIOPHARMA LIMITED	134
BIO-RAD LABORATORIES INC.	134
BIOGEN IDEC INC.	134
BIONEER	134
BRISTOL-MYERS-SQUIBB	134
CENIX BIOSCIENCE GMBH	135
CERULEAN PHARMA INC.	135
CLONTECH LABORATORIES INC.	135
CONSTAB PHARMACEUTICAL	135
DEBIOPHARMA	135
DICERNA PHARMACEUTICALS	136
DURECT CORPORATION	136
EXIQON A/S	136
GENSIGNIA INC.	136
GLAXOSMITHKLINE	136
HALO-BIO	137
ICO THERAPEUTICS INC.	137
ILLUMINA INC.	137
INTEGRATED DNA TECHNOLOGIES	137

TOPIC	PAGE NO.
ISIS PHARMACEUTICALS	137
LIFE TECHNOLOGIES (TO BE MERGED WITH THERMO FISHER)	138
LIQUIDIA TECHNOLOGIES	138
MARINA BIOTECH	138
MERCK & CO. INC.	138
MIRNA THERAPEUTICS	138
MIRUS BIO LLC	139
MODERNA THERAPEUTICS INC.	139
MONSANTO COMPANY	139
MYRIAD GENETICS INC.	139
NOVARTIS AG	139
NOXXON PHARMA AG	140
OPHTHOTECH	140
PFIZER INC.	140
PHARMAXIS LTD	140
PHASERX	140
PROGENITOR LABS LIMITED	141
PROSENSA	141
QIAGEN NV	141
QUARK PHARMACEUTICALS INC.	141
REGADO BIOSCIENCES INC.	141
REGULUS THERAPEUTICS INC.	142
ROCHE HOLDING AG	142
ROSETTA GENOMICS	142
RXI PHARMACEUTICALS CORP.	142
SANOFI	142
SANTARIS PHARMA A/S	143
SAREPTA THERAPEUTICS	143
SIGMA-ALDRICH	143
SILENCE THERAPEUTICS	143
SYNGENTA AG	143
TEKMIRA PHARMACEUTICALS CORP	144
THERMO FISHER SCIENTIFIC INC.	144

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 MICRORNA DATABASES	12
TABLE 2 COMPUTATIONAL TOOLS FOR MIRNA TARGET PREDICTION	13
TABLE 3 GLOBAL PHARMACEUTICAL MARKET, MARKET SHARES BY REGION AND TOP COMPANIES (%/\$ MILLIONS/\$ BILLIONS)	17
TABLE 4 COMPARISON OF U.S. AND EUROPEAN PATENT SYSTEMS	24
TABLE 5 PATENT AND PATENT APPLICATION SEARCHES IN RNAI MARKETPLACE USING VARIOUS KEY WORDS, AS OF AUGUST 2013	27
TABLE 6 PATENTS AND PATENT APPLICATIONS FOR RNAI DRUG COMPANIES, AS OF AUGUST 2013	28
TABLE 7 RECOMMENDED RNAI DELIVERY METHODS	39
TABLE 8 GLOBAL REAGENT AND RESEARCH TOOL FOR DNA AND RNA RESEARCH MARKET, THROUGH 2016 (\$ BILLIONS)	41
TABLE 9 GLOBAL RNAI RESEARCH TOOL AND REAGENT MARKET, THROUGH 2018 (\$ MILLIONS)	43
TABLE 10 MAJOR OBSTACLES FOR RNAI DRUG DELIVERY	48
TABLE 11 RNAI DRUG DELIVERY APPROACHES	50
TABLE 12 PROPRIETARY DELIVERY PLATFORMS	66
TABLE 13 DELIVERY SYSTEMS FROM SILENCE'S INVOLVEMENT	69
TABLE 14 ISIS PHARMACEUTICALS ANTISENSE DRUG CANDIDATES	76
TABLE 15 ISIS PHARMACEUTICALS REVENUE, PROFIT AND STOCK PRICES (\$ MILLIONS)	77
TABLE 16 RIBOZYME-BASED THERAPIES IN PRECLINICAL CANCER MODELS	79
TABLE 17 APTAMERS AND THEIR TARGETS	80
TABLE 18 APTAMER DRUGS IN VARIOUS CLINICAL STAGES	81
TABLE 19 RNAI THERAPEUTICS TARGETING MICRORNA	84
TABLE 20 SUMMARY OF RNAI-RELATED SOFTWARE	87
TABLE 21 ALNYLAM'S OWN, PARTNERED AND LICENSED PROGRAMS	90
TABLE 22 ARROWHEAD RESEARCH CORPORATION DRUG PIPELINE	91
TABLE 23 RNAI DRUG PIPELINE FROM MARINA BIOTECH	91
TABLE 24 TEKIRA'S RNAI PIPELINE PROGRAMS	92
TABLE 25 BENITEC IN-HOUSE AND OUT-LICENSED PIPELINES	93
TABLE 26 SILENCE THERAPEUTICS DRUG PIPELINE	94
TABLE 27 BIONEER'S RNAI DRUG PROGRAMS	95
TABLE 28 PHASERX'S PIPELINE PROGRAMS	95
TABLE 29 DICERNA'S EMERGING PIPELINE	96
TABLE 30 RXI PHARMACEUTICALS PIPELINE	96
TABLE 31 QUARK DEVELOPMENT PIPELINE	97
TABLE 32 COMPARISON OF NOTABLE RNA THERAPEUTICS COMPANIES	98
TABLE 33 ESTIMATED MARKET SIZE FOR THERAPEUTIC APPLICATIONS AND GEOGRAPHIC DISTRIBUTION OF RNA DRUG COMPANIES (DOLLAR VALUES AND PERCENTAGES)	99
TABLE 34 PUBLICATIONS REGARDING MICRORNA AND DISEASES, AS OF AUGUST 2013	101
TABLE 35 GLOBAL BIOMARKER MARKET, THROUGH 2015 (\$ BILLIONS)	102
TABLE 36 MIRNAS IN VARIOUS CANCER TYPES	103
TABLE 37 MIRNA DYSREGULATION AND COLORECTAL CANCER	106

TABLE HEADING	PAGE NO.
TABLE 38 STUDIES ON THE ASSOCIATION BETWEEN MIRNA DYSREGULATION AND STAGING OR PROGNOSIS OF COLORECTAL CANCER	107
TABLE 39 MICRORNA UP AND DOWN REGULATION IN LUNG CANCER	109
TABLE 40 IDEAL BIOMARKER CRITERIA	109
TABLE 41 HURDLES TO OVERCOME FOR MICRORNAS TO BE GOOD BIOMARKERS	110
TABLE 42 CANCER PROFILING, THROUGH 2015 (\$ BILLIONS)	112
TABLE 43 GLOBAL MICRORNA RESEARCH MARKET, THROUGH 2017 (\$ MILLIONS)	114
TABLE 44 GLOBAL MICRORNA DIAGNOSTIC AND MICRORNA PROFILING MARKET, THROUGH 2018 (\$ MILLIONS)	114
TABLE 45 NOVEL PLANT TRAITS ENGINEERED THROUGH RNAI	117

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, 2011-2018 (\$ MILLIONS)	7
FIGURE 1 SIMPLIFIED SCHEMATIC REPRESENTATION OF THE RNAI MECHANISM	10
FIGURE 2 THERMO FISHER RNAI PRODUCT SELECTION	32
FIGURE 3 GLOBAL RNAI RESEARCH TOOL AND REAGENT MARKET, 2011-2018 (\$ MILLIONS)	43
FIGURE 4 SCHEMATIC COMPOSITION OF STABLE NUCLEIC ACID LIPID PARTICLE TECHNOLOGY	55
FIGURE 5 MODIFICATIONS TO SIRNA BACKBONES AND BASES	59
FIGURE 6 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER BACKBONE STRUCTURE	60
FIGURE 7 DESIGNING HIGHLY ACTIVE SIRNAS FOR RNAI THERAPEUTICS	85
FIGURE 8 ROSETTA GENOMICS PIPELINE	112